As AMR renders antibiotics ineffective, untreatable infections will make routine procedures increasingly risky.
Jim O'Neill
Jim O'Neill is visiting fellow at the think-tank Bruegel and Chairman of the Review on Antimicrobial Resistance.
About the author
Jim O'Neill, a former chairman of Goldman Sachs Asset Management, is Commercial Secretary to the UK Treasury, Honorary Professor of Economics at Manchester University, a visiting research fellow at the economic think-tank Bruegel, and Chairman of the Review on Antimicrobial Resistance.
Latest Posts
Content Feed
Advertisement
